CN114868820A - 一种桑叶黑茶固体饮料的生产工艺及在制备降脂减肥的制剂中的应用 - Google Patents
一种桑叶黑茶固体饮料的生产工艺及在制备降脂减肥的制剂中的应用 Download PDFInfo
- Publication number
- CN114868820A CN114868820A CN202210617467.5A CN202210617467A CN114868820A CN 114868820 A CN114868820 A CN 114868820A CN 202210617467 A CN202210617467 A CN 202210617467A CN 114868820 A CN114868820 A CN 114868820A
- Authority
- CN
- China
- Prior art keywords
- solid beverage
- fat
- mulberry leaf
- group
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007787 solid Substances 0.000 title claims abstract description 60
- 235000013361 beverage Nutrition 0.000 title claims abstract description 55
- 240000000249 Morus alba Species 0.000 title claims abstract description 26
- 235000008708 Morus alba Nutrition 0.000 title claims abstract description 26
- 235000019225 fermented tea Nutrition 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 244000269722 Thea sinensis Species 0.000 claims abstract description 41
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 28
- 235000020279 black tea Nutrition 0.000 claims abstract description 28
- 230000001603 reducing effect Effects 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 238000007873 sieving Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 7
- 235000014620 theaflavin Nutrition 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 claims description 4
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 claims description 4
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 claims description 4
- 229940026509 theaflavin Drugs 0.000 claims description 4
- 230000033001 locomotion Effects 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 21
- 235000009200 high fat diet Nutrition 0.000 abstract description 20
- 241000894006 Bacteria Species 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 6
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 235000020510 functional beverage Nutrition 0.000 abstract description 2
- 238000013116 obese mouse model Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 51
- 210000004185 liver Anatomy 0.000 description 19
- 210000005228 liver tissue Anatomy 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 238000013218 HFD mouse model Methods 0.000 description 14
- 230000037396 body weight Effects 0.000 description 12
- 208000008589 Obesity Diseases 0.000 description 11
- 235000020824 obesity Nutrition 0.000 description 11
- 210000000577 adipose tissue Anatomy 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 235000013616 tea Nutrition 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 201000010063 epididymitis Diseases 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108010023302 HDL Cholesterol Proteins 0.000 description 7
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- 241000192125 Firmicutes Species 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 235000021590 normal diet Nutrition 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 241000605059 Bacteroidetes Species 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 235000009569 green tea Nutrition 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 241000702460 Akkermansia Species 0.000 description 3
- 241000606125 Bacteroides Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 241000425347 Phyla <beetle> Species 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 210000003486 adipose tissue brown Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000013238 high-fat diet model Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940040461 lipase Drugs 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 1
- 235000020927 12-h fasting Nutrition 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 241000731710 Allobaculum Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 101100154912 Mus musculus Tyrp1 gene Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000192497 Oscillatoria Species 0.000 description 1
- 241000266824 Oscillospira Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241001261005 Verrucomicrobia Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- -1 polyphenol compounds Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000008118 thearubigins Nutrition 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/30—Further treatment of dried tea extract; Preparations produced thereby, e.g. instant tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/163—Liquid or semi-liquid tea extract preparations, e.g. gels, liquid extracts in solid capsules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/18—Extraction of water soluble tea constituents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明属于功能食品和饮料领域,具体涉及一种桑叶黑茶固体饮料的生产工艺及在制备降脂减肥的制剂中的应用。实验研究表明,本发明桑叶黑茶固体饮料对高脂饮食肥胖小鼠的降脂减肥作用,还能够有效抑制F/B值升高,回调有益菌的丰度,有效改善因高脂饮食导致的肠道菌群紊乱,因而能够用于降脂减肥,具有较大的实用价值。
Description
技术领域
本发明属于功能食品和饮料领域。具体涉及一种桑叶黑茶固体饮料的生产工艺及在制备降脂减肥的制剂中的应用。
背景技术
当前社会高脂饮食(High-fat diet,HFD)导致了超重、肥胖等一系列问题出现,与肥胖相关的高血压、糖尿病、高胆固醇血症等慢性疾病的发病率逐年上升[1]。饮食干预是治疗肥胖的重要非药物手段,从我国丰富的天然产物资源中筛选具有降脂减肥作用的膳食功能因子,开发固体饮料或者功能食品,从而干预肥胖的发展成为重要的饮食发展趋势。
黑茶作为我国特有的后发酵茶,在细胞培养、动物模型和人群临床实验中,均表现出良好的调节代谢综合征[2]及肠道菌群[3,4]等功能,其减肥功效显著。表没食子儿茶素没食子酸酯((-)-Epigallocatechin gallate,EGCG)是绿茶中含量最高的儿茶素单体[5,6],可通过调节食欲[7],影响棕色脂肪组织活性[8],抑制脂肪细胞增殖分化[9]与脂滴积累[10]等多个途径减轻体重降低体脂。茶黄素(Theaflavins,TF)是红茶发酵过程中儿茶素进一步氧化产物,研究表明茶黄素可有效抑制脂肪酸的积累[11],抑制脂肪酶表达[12],与茶红素、茶褐素联用还可正向调节试验动物的肠道菌群种类和丰度[3],从多个方面辅助降脂减肥。
桑叶早在2002年被国家***法监司列为新资源食品,成为药食同源的天然植物。其主要活性成分桑叶黄酮、桑叶多糖、1-脱氧野尻霉素(1-deoxyrijimycin,DNJ)等,通过抑制脂肪酶[13]、糖苷酶[14]、增加脂联素抑制脂质过氧化[15]等途径减少脂肪合成,加速脂肪代谢,同时调节肠道菌群[16],从而达到降脂减肥效果。我国为茶叶与桑叶种植大国,充分开发两者资源及其它功能成分进行降脂减肥产品的开发,对振兴乡村经济具有非常重要的意义,也对广大肥胖患者是福音。该固体饮料具体通过何种机制调节HFD小鼠肠道菌群达到降脂减肥作用,仍需深入探究,以进一步提高和清晰解析其减肥效果及作用机理。
参考文献
[1]中国居民营养与慢性病状况报告(2020年)[J].营养学报,2020,42(06):521.
[2]李勤,黄建安,傅冬和,等.茶叶减肥及对人体代谢综合征的预防功效[J].中国茶叶,2019,41(05):7-13.
[3]蒋慧颖,马玉仙,曾文治,等.茶黄素、茶红素与茶褐素对高脂饮食大鼠肠道菌群的影响[J].食品工业科技,2018,39(20):274-279+351.
[4]徐正刚,吴良,***,等.黑茶发酵过程中微生物多样性研究进展.生物学杂志[J].2019,36(03):92-95.
[5]宛晓春.茶叶生物化学[M].北京:中国农业出版社,2006.
[6]严煜钧,刘仲华,林勇,等.茶叶中EGCG对非酒精性脂肪肝大鼠的调脂保肝作用研究[J].茶叶科学,2014,(3):221-229.
[7]刘冬敏,黄建安,刘仲华,等.茶及其多酚类化合物调节肥胖及并存症的研究进展[J].基因组学与应用生物学,2019,38(12):5603-5615.
[8]商悦,李毅,陈淑珍,等.茶多酚EGCG对小鼠棕色脂肪代谢的影响[J].科技导报,2014,32(11):21-25.
[9]郑国栋,徐峰,吴少福,等.绿茶成分对3T3-L1细胞的细胞增殖及脂肪代谢的影响[J].中国食品学报,2012,12(10):10-15.
[10]管巧丽,吴晓云,李芳,等.EGCG通过激活AMPK、抑制PPARγ调控3T3-L1脂肪细胞中脂滴蓄积[J].食品科学,2021,42(23):152-161.
[11]LIN C L,HUANG H C,LIN J K.Theaflavins attenuate hepatic lipidaccumulation through activating AMPK in human HepG2 cells[J].Journal of lipidresearch,2007,48(11):2334-2343.
[12]YEH C W,CHEN W J,CHIANG C T,et al..Suppression of fatty acidsynthase in MCF-7breast cancer cells by tea and tea polyphenols:a possiblemechanism for their hypolipidemic effects[J].The Pharmacogenomics Journal,2003,3(5):267-276.
[13]高畅,胡利,迟原龙,等.桑叶黄酮对胰脂肪酶的抑制作用[J].食品科技,2017,42(05):194-198.
[14]侯启瑞,钱忠瑶,李龙,等.桑叶1-脱氧野尻霉素对鹅脂质代谢的影响[J].蚕业科学,2020,46(03):387-392.
[15]王祖文,秦樱瑞,黄先智,等.桑叶-苦瓜混合粉对正常小鼠血糖血脂和抗氧化能力的影响[J].食品科学,2019,40(09):166-172.
[16]LI R,XUE Z,LI S,et al..Mulberry leaf polysaccharides ameliorateobesity through activation of brown adipose tissue and modulation of the gutmicrobiota in high-fat diet fed mice[J].Food&Function,2022,13(2):561-573.
[17]王蝶.茶叶对肥胖大鼠的减肥作用及机制研究[D].湖南农业大学,2012.
[18]赵伟,孙国志.不同种实验动物间用药量换算[J].畜牧兽医科技信息,2010,(5):52-3.
[19]张素珍,李思施,韦婷婷,等.高脂高糖与高纤维膳食对小鼠肠道菌群影响的比较[J].中国现代医学杂志,2014,24(20):37-41.
[19]ZHANG S Z,LI E S,WEI T T,et al.Comparison of the effects of highfat and sucrose diet and high fibre diet on the intestinal microbiota of mice[J].China Journal of Modern Medicine,2014,24(20):37-41.
[20]DING Q,ZHANG B,ZHENG W,et al..Liupao tea extract alleviatesdiabetes mellitus and modulates gut microbiota in rats induced bystreptozotocin and high-fat,high-sugar diet[J].Biomedicine&Pharmacotherapy,2019,118:109262.
[21]MICHELS N,ZOUIOUICH S,VANDERBAUWHEDE B,等.Human microbiome andmetabolic health:An overview of systematic reviews[J].Obesity Reviews:AnOfficial Journal of The International Association for The Study of Obesity,2022:e13409.
[22]马文玉,冯世秀,陈乃宏.嗜黏蛋白艾克曼菌的药理作用研究进展[J].中国中药杂志,2021,46(11):2760-2765.
[23]DE VOS W,TILG H,VAN HUL M,et al.Gut microbiome and health:mechanistic insights[J].Gut,2022.
[24]BELL H,REBERNICK R,GOYERT J,et al.Reuterin in the healthy gutmicrobiome suppresses colorectal cancer growth through altering redox balance[J].Cancer Cell,2021.
[25]LIéVIN-LE MOAL V,SERVIN A.Anti-infective activities oflactobacillus strains in the human intestinal microbiota:from probiotics togastrointestinal anti-infectious biotherapeutic agents[J].ClinicalMicrobiology Reviews,2014,27(2):167-199.
[26]韩岗,马婧,陶士珩,等.厚壁菌门细菌及其祖先蛋白的氨基酸偏好性研究[J].安徽农业科学,2011,39(30):18408-18410.
[26]HAN G,MA J,TAO S H,et al.The study of amino acid biases infirmicutes and their ancestral proteome[J].Journal of Anhui AgriculturalSciences,2011,39(30):18408-18410.
[27]KIM K,GU W,LEE I,et al.High fat diet-induced gut microbiotaexacerbates inflammation and obesity in mice via the TLR4 signaling pathway[J].PloS One,2012,7(10):e47713.
[28]王佳丽,修成奎,杨静,等.人参三七川芎提取物对高糖高脂诱导血管衰老小鼠肠道菌群的影响[J].中国中药杂志,2020,45(12):2938-2946.
[29]SANMIGUEL C,GUPTA A,MAYER E.Gut microbiome and obesity:aplausible explanation for obesity[J].Current Obesity Reports,2015,4(2):250-261.
[30]F,LEY R E,SONNENBURG J L,et al.Host-bacterial mutualismin the human intestine[J].Science,2005,307(5717):1915-1920.
[31]HOOPER L,WONG M,THELIN A,et al..Molecular analysis of commensalhost-microbial relationships in the intestine[J].Science(New York,NY),2001,291(5505):881-884.
[32]HOOPER L V.Bacterial contributions to mammalian gut development[J].Trends in Microbiology,2004,12(3):129-134。
发明内容
本发明人通过HFD小鼠进行低、中、高剂量桑叶黑茶固体饮料的灌胃,对比正常组、模型组和阳性药组,对小鼠的体重、脂肪重、血脂水平、脂肪和肝脏组织病理学观察以及肠道菌群测序,
本发明提供一种桑叶黑茶固体饮料的生产工艺,其特征在于,包括如下步骤:
1)称量:分别称取桑叶和黑茶;
2)粉碎过筛:分别把桑叶和黑茶粉碎并过筛;
3)纯水回流提取:把桑叶与黑茶分别75℃-80℃纯水提取;
4)真空浓缩:在真空气压为-0.02Mp~-0.095Mp,温度60℃~80℃的条件下浓缩;
5)喷雾干燥:采用喷雾干燥法得到桑叶和黑茶提取物粉末,优选使用设置进风温度为165℃~190℃,出风温度为75℃~85℃;
6)过筛:分别收取桑叶与黑茶提取物粉末,100%过振荡筛;
7)把桑叶与黑茶按照1:1比例进行混合20-40min。
优选地,第2)步中,过10目筛。
优选地,第3)步中回流提取1小时/次,共进行2次,其通过离心泵抽提取料液进行连续回流,使提取罐内物料保持高温状态。
优选地,第4)步中浓缩至固形物含量为达到30%-50%。
优选地,第5)步使用LPG50型干燥塔,设置进风温度为165℃~190℃,出风温度为75℃~85℃,雾化机电机频率为300Hz~400Hz,出料频率为25Hz~35Hz进行喷雾干燥。
优选地,第6)步中100%过80目振荡筛。
优选地,第7)步中把黑茶提取物、桑叶提取物、茶黄素与EGCG按照20:20:3:3比例进行混合30min。
优选地,第7)步具体操作是:将黑茶和桑叶提取物按设定的重量比进行混合,在三维运动混合机中充分混合20-40分钟,主轴转速为10-25r/mjn;将物料在制粒机中过筛制粒;对物料进行干燥,温度控60--70℃之间,干燥至水分≤5%,得到固体饮料。
本发明还提供所述的生产工艺得到的复合提取物,优选进一步制作成固体饮料。
本发明进一步提供所述的复合提取物或固体饮料在制备降脂减肥的制剂中的应用,优选地所述制剂是饮料、食品、食品添加剂,或药物。
实验研究表明,本发明桑叶黑茶固体饮料对高脂饮食肥胖小鼠的降脂减肥作用,使得HFD小鼠体质量的增量和脂肪湿重均明显减少,TC、TG、LDL-C水平得到显著改善,肝脏及脂肪组织细胞的变性得到缓解,同时该桑叶黑茶固体饮料还能够有效抑制F/B值升高,回调有益菌的丰度,有效改善因高脂饮食导致的肠道菌群紊乱,因而能够用于降脂减肥,具有较大的实用价值。
附图说明
图1桑叶黑茶固体饮料制备工艺。
图2不同处理组小鼠体重变化。其中,CK:正常组,MG:模型组,L:固体饮料低剂量组,M:固体饮料中剂量组,H:固体饮料高剂量组,PG:阳性药组。n=8,x±SD。与CK组比较,“#”表示差异性显著(P<0.05),“##”表示差异性极显著(P<0.01);与MG组比较,“*”表示差异显著(P<0.05),“**”表示差异极显著(P<0.01),下同。
图3不同处理组小鼠脂肪湿重及比重。
图4不同处理组小鼠附睾脂肪切片(×40)。
图5不同处理组小鼠肾周脂肪切片(×40)。
图6不同处理组小鼠肝脏组织切片(×40)。
图7不同处理组小鼠肝脏ALT与AST活性。
图8不同处理组小鼠血清TG、TC、LDL-C、HDL-C浓度。
图9样品稀释曲线。
图10各处理组小鼠肠道菌群PCoA分析。
图11各处理组肠道菌群在门水平上的丰度。
图12各组小鼠肠道菌群在属水平上相对丰度热图。
具体实施方式
实施例一
按下述工艺制备桑叶黑茶固体饮料(如图1所示):
将合格的黑茶茶原料100kg,粉碎成10目,过筛(10目筛网),纯水回流提取具体是称量100kg原料,1吨纯水加热75℃-80℃之间,1小时/次×2次(通过离心泵抽提取料液进行连续回流,使提取罐内物料保持高温状态),采用真空浓缩(-0.02Mp-0.095Mp,温度60℃-80℃,浓缩至40%固形物),本实施例采用-0.05Mp,70℃的条件。然后进行喷雾干燥(LPG50型干燥塔,进风温度165℃-190℃,出风温度75℃-85℃,雾化电机频率300Hz-400Hz,进料频率25Hz-35Hz),干燥至水分<5%,然后100%过80目振荡筛得到黑茶提取物备用。
按同样的流程提取桑叶提取物备用。
将黑茶提取物、桑叶提取物、50%茶黄素与98%EGCG按设定的重量比(本实施例按20:20:3:3)进行混合,在三维运动混合机中充分混合30分钟,主轴转速为15r/min,用食用级PE塑料袋转移至下步工序;将物料在制粒机中用20目筛制粒,用不锈钢盘转移至下步工序;对物料进行干燥,温度控60-70℃之间,干燥至水分≤5%,用PE塑料袋转移至下步工序或进行内包,得到桑叶黑茶固体饮料。
实施例二
1、材料
黑茶提取物、桑叶提取物按实施例一的方法制备;茶黄素(含量>50%)、EGCG(含量>98%),可购自湖南艾嘉生物科技有限公司。
2、方法
试验动物:雄性C57BL/6J小鼠,SPF级,体重18~20g,由湖南斯莱克景达试验动物有限公司提供,许可证号SCXK(湘)2019-0004。所有动物实验均经湖南农业大学生物医学研究伦理委员会批准[批准号:伦审科2021第(96)号]。动物饲养于湖南农业大学茶叶研究所动物房,饲养环境条件为洁净环境,温度(24±2)℃,相对湿度45%~65%,定时照明(9:00~21:00)。
动物分组及模型建立:根据《保健食品功能评价指导原则(2020年版)(征求意见稿)减肥功能评价方法》(以下简称《方法》),所有小鼠适应性喂养3d后,随机分为2组:8只给予正常饲料的空白组(CK),52只给予60%高脂饲料的高脂饮食组,饲料成分见表1。为保证肥胖模型建立,喂养2周后,排除高脂饮食组中体重靠后的12只小鼠,剩余40只随机分为5组,每组8只,分别为模型组(MG)、低剂量组(L)、中剂量组(M)、高剂量组(H)、阳性药组(PG),继续给予高脂饲料喂养4周。
表1正常饲料及高脂饲料配方(g)
动物喂养及灌胃:由成人(60kg)每日推荐饮茶量9g[17]得出150mg/kg·bw,根据《方法》建议,以其5倍、10倍、15倍分别为低、中、高浓度的固体饮料对HFD小鼠进行灌胃。因固体饮料中实际功效成分占比为51%,故低浓度=150mg/kg·bw×5×51%=382.5mg/kg·bw,中浓度=150mg/kg·bw×10×51%=765.0mg/kg·bw,高浓度=150mg/kg·bw×10×51%=1147.5mg/kg·bw。
阳性药物选用市售具减肥功效的中成药,按照说明书成人每日服用60粒(总重9g),据实验动物用药量换算[18]后得到阳性药物灌胃剂量=150mg/kg·bw×9.1=1365mg/kg·bw。空白组及模型组灌胃蒸馏水作为对照,灌胃期为6周,各组小鼠喂养及灌胃内容见表2。
表2小鼠的喂养及灌胃
动物样品的采集:6周灌胃期结束后,收集小鼠粪便保存至冻存管中,于-80℃备用。禁食12h,次日用戊巴比妥钠水溶剂麻醉后进行眼球取血,静置2~4小时后,于4℃、3000r/min条件下离心15min,取上层血清保存在-80℃待测。小鼠断颈处死后,取其肝脏、附睾脂肪及肾周脂肪,于预冷的生理盐水中漂洗除去附着的血液,滤纸吸干后称重,所得肝脏组织一份4%多聚甲醛固定,脂肪组织一份脂肪固定液固定,固定,其余-80℃保存备用。
指标测定及处理:
1)体重、肝重、脂肪组织湿重的测定:对各处理组小鼠体重、肝重、不同部位脂肪组织湿重进行称量,计算固体饮料干预前后的差值并分析。
2)血清和肝脏组织中指标的测定:取小鼠眼球血并静置2~4h后,于4℃、3000r/min条件下离心10min,取上清,按照试剂盒说明,测定小鼠血清中总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)含量。
准确称取小鼠肝脏组织重量,按重量(mg):体积(μL)=1:9的比例加入9倍体积的0.9%的生理盐水,于冰水浴条件下机械匀浆,制备成10%的匀浆液,在3000r/min条件下离心10min,取上清,按照试剂盒说明,测定小鼠肝脏中谷丙转氨酶(ALT)、谷草转氨酶(AST)的活性。
3)肝脏及脂肪组织病理学观察:取各处理组小鼠肝脏同一部位肝脏组织及同一侧肾周脂肪、附睾脂肪组织,用4%多聚甲醛及脂肪固定液分别固定,经流水冲洗,梯度乙醇脱水,二甲苯脱水,透蜡,包埋,脱蜡切片,采用苏木精-伊红(hematoxylin-eosin,HE)染色方法,光镜下观察肝脏及脂肪组织病理变化。
4)肠道菌群检测:每组随机选取6只小鼠,每只小鼠收集2~3颗粪便保存于2mL无菌离心管中,采用干冰送样方法寄送至上海派森诺生物科技有限公司。对通过质检的样品进行PCR扩增,以Illumina为测序平台建库及测序,对其16S rDNA V3V4(a)区肠道菌群进行α多样性、β多样性及基于门、属水平物种构成分析。
数据处理与统计分析:采用GraphPad Prism 8.0软件进行统计分析并作图,试验数据均以平均值±标准差表示。多组间数据比较采用单因素方差分析,P<0.05表示差异显著,P<0.01表示差异极显著。
实验结果与分析
1、小鼠体重变化趋势及增量
从建模期到灌胃期共计10周,对各组小鼠体重进行记录并分析(图2中A),CK组体重变化趋势较为平稳,MG组体重一直保持上升趋势,其他各组体重增幅均在给药后的第5周表现出下降趋势。
从造模期开始到给药期结束,对不同处理组小鼠体重增加情况分析(图2中B)。与CK组比较,MG组体重极显著增加163%(P<0.01),固体饮料各组和PG组体重增量均与CK组无显著差异,属于正常体重增长;同时,与MG组比较,各组体重增量均表现出极显著降低,L、M、H组分别减少66%、73%、78%,均优于阳性药组减少增重38%的减肥效果。结果说明黑茶固体饮料能有效控制高脂饮食小鼠的体重增量。
2、小鼠脂肪含量及脂肪细胞形态观察
对各组小鼠的肾周脂肪、附睾脂肪进行称量后得到脂肪湿重结果(图3中A)。与正常饮食相比,高脂饮食可导致小鼠肾周及附睾部位脂肪重量成倍增加(462%);对HFD小鼠进行不同浓度黑茶固体饮料灌胃后,各组脂肪湿重均表现出显著减少情况(P<0.05),L、M、H组及PG组分别减少49%、68%、72%和37%,其中灌胃中、高剂量固体饮料的小鼠该部位脂肪重量与正常饮食组小鼠无异。同时,固体饮料可显著减少脂肪组织在小鼠体内的占比(图3中B)。结果表明,黑茶固体饮料可显著减少高脂小鼠附睾及肾周脂肪湿重,优于本试验所选阳性药,且呈剂量依赖趋势。
为进一步观察各组小鼠脂肪组织的形态变化,对各组小鼠的肾周脂肪、附睾脂肪组织进行石蜡切片并染色观察(图4、图5),正常饮食组两个部位脂肪组织的细胞形态规则,排列整齐紧密;高脂饮食组小鼠脂肪细胞呈无序状排列,细胞出现充脂和体积增大,呈现不同程度的分化。通过灌胃固体饮料及阳性药,该情况得到不同程度的改善,其中M组接近于CK组的正常形态,H组细胞比CK组排列更为紧密,细胞体积更小。
由上述结果可知,黑茶固体饮料可有效抑制高脂饮食带来的体内脂肪比重增加,改善HFD小鼠肾周、附睾脂肪组织细胞的体积增大,抑制脂肪细胞变性,进而减轻肥胖给机体带来的不良影响。
3、小鼠肝脏组织病理学观察及肝脏转氨酶指标
对各组小鼠的肝组织切片进行H&E染色(图6),观察到正常饮食小鼠肝细胞大小均匀,排布整齐,肝窦排列有序,未见脂滴。高脂饮食小鼠肝细胞内有大量脂滴聚集,肝窦紊乱,出现空泡,肝脏细胞结构不全。阳性药组小鼠肝脏细胞状况改善明显,细胞排列较为整齐。通过固体饮料灌胃,三个剂量组小鼠脂肪变性情况均比模型组轻。L组小鼠肝脏组织中脂滴聚集及空泡情况较MG组明显减少,存在一定数量脂滴;M组肝组织切片显著改善,细胞内有少量小脂滴,肝窦排列清晰有序;H组未见明显脂滴,肝细胞排布均匀。
各处理组小鼠肝脏组织进行匀浆后检测ALT及AST的活力结果(图7)。与CK组相比,MG组ALT活力显著增加,结合图6肝脏组织切片结果,提示高脂饮食可能导致肝脏出现炎症反应;与MG组相比,各试验组及阳性药组的ALT活力均显著降低(P<0.05),且与CK组无显著差异。
由以上结果可知,本试验所用固体饮料具有缓解肝脏脂肪过度积聚与变性、改善肝脏可能因肥胖出现的炎症等问题的效果。
4、小鼠血脂水平
研究了黑茶固体饮料对HFD小鼠血脂水平的影响,对不同处理组小鼠血清TG、TC、LDL-C及HDL-C水平进行测定(分别见图8中A、B、C、D)。结果显示,与CK组相比,MG组血清HDL-C和TC水平显著增加,说明高脂饮食会明显增加小鼠高密度脂蛋白胆固醇在血清中的浓度,增加血清总胆固醇水平。而通过固体饮料干预,H组血清HDL-C及TC水平得到控制,呈极显著差异(P<0.01)。本试验低、中剂量未显现出明显降血脂效果,但高剂量固体饮料降低血脂的效果优于本试验所用阳性药组,高剂量固体饮料仍具有降低血清高密度脂蛋白胆固醇的效果。
5、小鼠肠道菌群测序
通过各组小鼠的16S rDNA V3V4(a)区肠道菌群测序,进行α多样性、β多样性及基于门、属水平物种构成的分析,初步探究黑茶固体饮料在小鼠体内的降脂机制。
各处理组样品物种丰度分析:对样本量的饱和情况进行分析后作稀释曲线(图9),随着测序数的增加,曲线越平缓,丰度减少趋势趋于平稳,表明测序结果已足够反映当前样本所包含的多样性,继续增加测序深度已无法检测大量尚未发现的新物种数目,样本测序量基本已覆盖所有类群,具有可信度。
各处理组小鼠肠道菌群Alpha分析:主坐标分析(Principal CoordinatesAnalysis,PCoA)是一种数据降维分析方法,用于将多维的数据转换为距离矩阵,研究数据间的相似性。经过6周黑茶固体饮料的干预,试验组肠道菌群组成结构发生了一定的偏移(图10)。MG组与CK组大部分位于第一主成分的异侧,说明高脂饮食导致HFD小鼠与正常饮食组小鼠的肠道菌群产生较大差异;L、M、H组大部分位于第一主成分的同侧,说明给予干预的三组高脂小鼠具有相似的肠道菌群构成;L、M、H组与MG组位于第二主成分的异侧,说明给予干预的三组小鼠与高脂饮食模型小鼠的肠道菌群组成差异较大。
各处理组小鼠肠道菌群构成分析:对各组小鼠肠道菌群在门水平上的组成进行分析发现,厚壁菌门、变形菌门和拟杆菌门是六个处理组中占比最高的三大菌门,所占比例之和均超过80%,此外占比靠前的还有疣微菌门、放线菌门等(图11)。在固体饮料对高脂小鼠干预6周后CK组、MG组、L组、M组、H组和PG组的厚壁菌门与拟杆菌门比值(F/B值)分别为5.23、14.72、3.08、5.56、2.57和14.07,可见MG组F/B值高于其他各组,H组最低。从本试验结果可以看出,在高脂饮食所诱导肥胖中,厚壁菌门的丰度与之呈正向关系,而拟杆菌门具有反向关系,这与前人诸多研究结论相符[19-21]。
为了更进一步探究黑茶固体对肠道菌群的影响,对各组小鼠肠道菌群在属水平上的种类和丰度进行了分析(图12)。各组小鼠肠道菌群中占主要比例的菌属有异杆菌属(Allobaculum)、颤螺菌属(Oscillospira)、乳杆菌属(Lactobacillus)、拟杆菌属(Bacteroides)、阿克曼菌属(Akkermansia)等。嗜黏蛋白艾克曼菌(Akkermansiamuciniphila)是一种于发现于2004年的益生菌[22],可发挥保护肠道屏障,减轻炎症的作用[23]。在本试验固体饮料的干预下,L、M、H组的阿克曼菌属丰度较正常组和模型组得到明显上调。乳杆菌属中包含多种乳酸杆菌,也属于肠道中的有益菌种,例如罗伊氏乳杆菌(L.reuteri)[24]、嗜酸乳杆菌(L.acidophilus)、鼠李糖乳杆菌(L.rhamnosus GG)[25]等,可保护肠道免疫***,抵御因肥胖造成的肠道菌群紊乱。在模型组中,乳杆菌属水平较正常组显著下调,中、高浓度固体饮料组和阳性药组小鼠肠道菌群中这一情况得到改善,对肠道有益的乳杆菌属丰度得到回调。本固体饮料可通过调节高脂饮食小鼠肠道细菌门、属的构成,降低F/B比值,回调有益菌属的丰度,保护肠道菌群的构成,减轻肥胖所带来的炎症发生。
本发明通过对HFD小鼠进行低、中、高剂量黑茶固体饮料的灌胃,对比正常组、模型组和阳性药组,从多个方面探究了该固体饮料对高脂饮食小鼠的减肥作用。通过对比正常组,发现高脂饮食小鼠的体重、脂肪组织湿重均显著增加,胆固醇水平明显上升,肝脏组织、脂肪组织的完整性受到不同程度破坏;给药干预后的HFD小鼠,对比HFD模型组,其体重和脂肪湿重的增量减少,血脂及胆固醇的水平有所改善,肝脏及脂肪组织细胞的变性得到缓解。上述结果表明,黑茶固体饮料能够降低HFD小鼠体重增量、减少HFD小鼠脂肪质量、减轻肝脏脂肪沉积及肝损伤情况。在对各组小鼠的肠道菌群进行检测分析后发现,高脂饮食会造成肠道菌群种类比例失调,其中以厚壁菌门占比增加、拟杆菌门占比减少导致的F/B比值增加为主。已有研究表明,厚壁菌门包括较多***,会更好地吸收热量从而导致肥胖,或通过参与内毒素的产生,诱导炎症的引发;而拟杆菌是一类厌氧革兰阴性杆菌,可吸收和降解人体肠道内的多糖,加快肠黏膜血管形成、维持肠道微生态平衡、增强宿主免疫力等功能。因此,本发明的固体饮料还能够有效抑制F/B值升高,回调有益菌的丰度,有效改善因高脂饮食导致的肠道菌群紊乱。
Claims (10)
1.一种桑叶黑茶固体饮料的生产工艺,其特征在于,包括如下步骤:
1)称量:分别称取桑叶和黑茶;
2)粉碎过筛:分别把桑叶和黑茶粉碎并过筛;
3)纯水回流提取:把桑叶与黑茶分别75℃-80℃纯水提取;
4)真空浓缩:在真空气压为-0.02Mp~-0.095Mp,温度60℃~80℃的条件下浓缩;
5)喷雾干燥:采用喷雾干燥法得到桑叶和黑茶提取物粉末,优选使用设置进风温度为165℃~190℃,出风温度为75℃~85℃;
6)过筛:分别收取桑叶与黑茶提取物粉末,100%过振荡筛;
7)把桑叶与黑茶按照1:1比例进行混合20-40min。
2.如权利要求1所述的生产工艺,其特征在于,第2)步中,过10目筛。
3.如权利要求1所述的生产工艺,其特征在于,第3)步中回流提取1小时/次,共进行2次,其通过离心泵抽提取料液进行连续回流,使提取罐内物料保持高温状态。
4.如权利要求1所述的生产工艺,其特征在于,第4)步中浓缩至固形物含量为达到30%-50%。
5.如权利要求1所述的生产工艺,其特征在于,第5)步使用LPG50型干燥塔,设置进风温度为165℃~190℃,出风温度为75℃~85℃,雾化机电机频率为300Hz~400Hz,出料频率为25Hz~35Hz进行喷雾干燥。
6.如权利要求1所述的生产工艺,其特征在于,第6)步中100%过80目振荡筛。
7.如权利要求1所述的生产工艺,其特征在于,第7)步中把黑茶提取物、桑叶提取物、茶黄素与EGCG按照20:20:3:3比例进行混合30min。
8.如权利要求1至7任一项所述的生产工艺,其特征在于,第7)步具体操作是:将黑茶和桑叶提取物按设定的重量比进行混合,在三维运动混合机中充分混合20-40分钟,主轴转速为10-25r/mjn;将物料在制粒机中过筛制粒;对物料进行干燥,温度控60--70℃之间,干燥至水分≤5%,得到固体饮料。
9.如权利要求1至8任一项所述的生产工艺得到的复合提取物,优选进一步制作成固体饮料。
10.如权利要求9所述的复合提取物或固体饮料在制备降脂减肥的制剂中的应用,优选地所述制剂是饮料、食品、食品添加剂,或药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210617467.5A CN114868820A (zh) | 2022-06-01 | 2022-06-01 | 一种桑叶黑茶固体饮料的生产工艺及在制备降脂减肥的制剂中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210617467.5A CN114868820A (zh) | 2022-06-01 | 2022-06-01 | 一种桑叶黑茶固体饮料的生产工艺及在制备降脂减肥的制剂中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114868820A true CN114868820A (zh) | 2022-08-09 |
Family
ID=82680509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210617467.5A Pending CN114868820A (zh) | 2022-06-01 | 2022-06-01 | 一种桑叶黑茶固体饮料的生产工艺及在制备降脂减肥的制剂中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114868820A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116762958A (zh) * | 2023-06-16 | 2023-09-19 | 广州市科贝思生物技术有限公司 | 一种桑叶提取物及其制备方法与应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130093371A (ko) * | 2012-02-14 | 2013-08-22 | 대구가톨릭대학교산학협력단 | 항고혈압, 항당뇨 및 항노화성 플라보노이드 함유 뽕나무 잎 추출물의 신규한 제조 방법 및 그 산물 |
CN103689565A (zh) * | 2013-11-21 | 2014-04-02 | 广州市体育科学研究所 | 一种减重降脂的植物固体饮料及其制备方法 |
CN104026283A (zh) * | 2014-05-20 | 2014-09-10 | 中华全国供销合作总社杭州茶叶研究所 | 一种降脂减肥保健功能茶 |
KR20150110378A (ko) * | 2014-03-21 | 2015-10-02 | (주)아모레퍼시픽 | 후발효차 추출물을 포함하는 조성물 |
CN105707318A (zh) * | 2016-02-24 | 2016-06-29 | 中国土产畜产进出口总公司 | 一种具有减肥功能的饮品组合物及其应用 |
CN111296825A (zh) * | 2019-11-15 | 2020-06-19 | 江苏隆力奇生物科技股份有限公司 | 一种减肥组合物及其制备方法与应用 |
CN111345375A (zh) * | 2020-04-23 | 2020-06-30 | 上海交通大学 | 一种减肥降脂的零能量黑茶功能饮料及其制备方法 |
-
2022
- 2022-06-01 CN CN202210617467.5A patent/CN114868820A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130093371A (ko) * | 2012-02-14 | 2013-08-22 | 대구가톨릭대학교산학협력단 | 항고혈압, 항당뇨 및 항노화성 플라보노이드 함유 뽕나무 잎 추출물의 신규한 제조 방법 및 그 산물 |
CN103689565A (zh) * | 2013-11-21 | 2014-04-02 | 广州市体育科学研究所 | 一种减重降脂的植物固体饮料及其制备方法 |
KR20150110378A (ko) * | 2014-03-21 | 2015-10-02 | (주)아모레퍼시픽 | 후발효차 추출물을 포함하는 조성물 |
CN104026283A (zh) * | 2014-05-20 | 2014-09-10 | 中华全国供销合作总社杭州茶叶研究所 | 一种降脂减肥保健功能茶 |
CN105707318A (zh) * | 2016-02-24 | 2016-06-29 | 中国土产畜产进出口总公司 | 一种具有减肥功能的饮品组合物及其应用 |
CN111296825A (zh) * | 2019-11-15 | 2020-06-19 | 江苏隆力奇生物科技股份有限公司 | 一种减肥组合物及其制备方法与应用 |
CN111345375A (zh) * | 2020-04-23 | 2020-06-30 | 上海交通大学 | 一种减肥降脂的零能量黑茶功能饮料及其制备方法 |
Non-Patent Citations (4)
Title |
---|
RUILIN LI ET AL: "Mulberry leaf polysaccharides ameliorate obesity through activation of brown adipose tissue and modulation of the gut microbiota in high-fat diet fed mice", 《FOOD&FUNCTION》, 24 December 2021 (2021-12-24), pages 561 - 573 * |
RUILIN LI ET AL: "Mulberry leaf polysaccharides ameliorate obesity through activation of brown adipose tissue and modulation of the gut microbiota in high-fat diet fed mice", 《FOOD&FUNCTION》, pages 561 - 573 * |
张茂清等: "《现代药理学与药物治疗基础》", 31 May 2019, 吉林科学技术出版社, pages: 542 - 543 * |
汤荃荃等: "黑茶桑叶固体饮料对高脂饮食小鼠的减肥作用", 《中国酿造》, vol. 41, no. 6, pages 164 - 170 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116762958A (zh) * | 2023-06-16 | 2023-09-19 | 广州市科贝思生物技术有限公司 | 一种桑叶提取物及其制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dong et al. | Effects of Nigella sativa seed polysaccharides on type 2 diabetic mice and gut microbiota | |
KR20120034482A (ko) | 지방세포 분화 유도에 관여하는 유전자의 발현을 억제함으로써 지방세포 분화 억제 효능을 갖는 락토바실러스 플란타룸 케이와이1032 및 이를 유효성분으로 함유하는 제품 | |
CN113209139B (zh) | 乳双歧杆菌MN-Gup改善肥胖及其特征肠道菌群用途 | |
Qian et al. | Effects of lactobacillus casei YBJ02 on lipid metabolism in hyperlipidemic mice | |
CN109010616A (zh) | 一种增加肠道益生菌、改善肠道菌群的纯植物制剂 | |
CN113142303A (zh) | 一种具有预防肥胖功效的酸奶及其制备方法 | |
CN114868820A (zh) | 一种桑叶黑茶固体饮料的生产工艺及在制备降脂减肥的制剂中的应用 | |
CN113197921A (zh) | 乳双歧杆菌MN-Gup及其菌剂在治疗2型糖尿病中的应用 | |
CN114632101B (zh) | 一种广东虫草减肥降脂护肝复方及其制备方法和应用 | |
Yi et al. | Effects of Lactobacillus fermentum CQPC04 on lipid reduction in C57BL/6J mice | |
Ansari et al. | A controlled fermented samjunghwan herbal formula ameliorates non-alcoholic hepatosteatosis in HepG2 Cells and OLETF rats | |
Yue et al. | Dietary strategies to promote the abundance of intestinal Akkermansia muciniphila, a focus on the effect of plant extracts | |
Zhang et al. | Tangduqing granules attenuate insulin resistance and abnormal lipid metabolism through the coordinated regulation of PPARγ and DGAT2 in type 2 diabetic rats | |
CN115369050B (zh) | 一株小克里斯滕森氏菌sj-2及其应用 | |
Li et al. | Nostoc flagelliforme capsular polysaccharides from different culture conditions improve hyperlipidemia and regulate intestinal flora in C57BL/6J mice to varying degrees | |
Liu et al. | The potential mechanisms of bergamot-derived dietary fiber alleviating high-fat diet-induced hyperlipidemia and obesity in rats | |
CN115053929B (zh) | 一种适合脂肪肝人群的配方奶粉及其制备 | |
CN113207960B (zh) | 改善肥胖的乳双歧杆菌MN-Gup发酵乳及制备方法 | |
Zhou et al. | Fuzhuan brick tea supplemented with areca nuts: Effects on serum and gut microbiota in mice | |
CN106728077B (zh) | 具有调节肠道菌群结构及防治便秘作用的组合物及其制备方法与应用 | |
CN109045070A (zh) | 一种防治非酒精性脂肪肝病的组合物 | |
CN110575507A (zh) | 薏仁在调节肠道微生物中的用途 | |
CN110123824B (zh) | 毛冬青皂苷a1的新用途 | |
KR101688126B1 (ko) | 고지혈증 또는 비만의 예방 또는 치료용 약제학적 조성물 및 이의 제조 방법 | |
Hao et al. | A study on the treatment effects of Crataegus pinnatifida polysaccharide on non-alcoholic fatty liver in mice by modulating gut microbiota |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |